BIIB34:BVMF
Biogen Inc BDR
230,10 R$
0,00%
(0,00) 1D
4 ნოე, 15:38:07 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
36,71 მლრდ.
Avg. vol.
9,00
Volume
0,00
52-wk high
230,10 R$
52-wk low
137,90 R$
Shares outstanding
147,82 მლნ.
No. of employees
8 ათ.
Mkt. cap
36,71 მლრდ.
Avg. vol.
9,00
Volume
0,00
52-wk high
230,10 R$
52-wk low
137,90 R$
Shares outstanding
147,82 მლნ.
No. of employees
8 ათ.
News stories
From web sources and news partners
Seeking Alpha
·
9 წუთის წინ
Growth funds limit losses as active managers deliver mixed October results, BofA says
The Motley Fool
·
20 წუთის წინ
No Matter What Happens to the S&P 500 in November, These 3 Dividend Stocks Belong in Your Portfolio
Yahoo! Finance Canada
·
1 საათის წინ
CABA,TRIN,RPC,FFIN,NXRT,GO,BLCO,CULP,VSNT,FRST,VIRC,KWY,ENTX,GRNT,BLIN,SSP,PCF,GAIA,NRGV,AFCG,APCX,KLTR,THRY,BETR | Stock Prices | Quote Comparison - Yahoo Finance
Bloomberg.com
·
1 დღის წინ
Wall Street Strategists Call Stock Rout a Fresh Reason to Buy
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOქრის ვიბახერ
Employees7,5 ათ.
Founded1978
Headquartersკემბრიჯი, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Websitebiogen.com